Loading clinical trials...
Loading clinical trials...
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Conditions
Interventions
Montanide (Registered Trademark) ISA-51 VG Adjuvant
H1299 Cell Lysates
+2 more
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
April 29, 2026
Primary Completion Date
December 30, 2033
Completion Date
December 30, 2035
Last Updated
April 24, 2026
NCT06043817
NCT06855771
NCT07144280
NCT07431827
NCT06758401
NCT06427941
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions